{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003639","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.749309+00:00","generated_at":"2026-06-18T03:47:07.644218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virios posts FY2022 net loss $12.2M; cash $7.0M; FDA meeting on IMC-1 Phase 3 in March","bullets":["Net loss Q4 2022 $2.0M ($0.11/share) vs $4.5M in Q4 2021; FY2022 net loss $12.2M ($1.11) vs $16.0M in FY2021.","Cash $7.0M at Dec 31, 2022; expects funding through mid-2024 for current ops but needs additional funds for IMC-1 FM trials.","End-of-Phase 2 meeting with FDA in March 2023 to discuss IMC-1 progression into Phase 3 development.","Patient enrollment complete for exploratory Long-COVID study; top-line results expected mid-2023.","R&D expenses decreased to $1.3M in Q4 2022 vs $2.9M in Q4 2021; FY2022 R&D $8.1M vs $10.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003639","json":"https://secwatch.observer/filing/0001558370-23-003639.json","markdown":"https://secwatch.observer/filing/0001558370-23-003639.md","text":"https://secwatch.observer/filing/0001558370-23-003639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/0001558370-23-003639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/tmb-20230314x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:47:07.644218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}